Contract notice
Section I: Contracting
authority
I.1) Name and addresses
NHS Blood and Transplant
500 North Bristol Park
Bristol
BS34 7QH
UK
Contact person: Jo Murphy
Telephone: +44 1179212718
E-mail: jo.murphy@nhsbt.nhs.uk
NUTS: UKK11
Internet address(es)
Main address: https://www.nhsbt.nhs.uk/
Address of the buyer profile: https://www.nhsbt.nhs.uk/
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://health-family.force.com/s/Welcome
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://health-family.force.com/s/Welcome
Tenders or requests to participate must be sent to the abovementioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
https://health-family.force.com/s/Welcome
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Managed Service Contract for the Provision of Secondary Blood Grouping & Sickle Cell Testing
II.1.2) Main CPV code
85111810
II.1.3) Type of contract
Services
II.1.4) Short description
NHSBT is looking to award a Managed Service Contract for the supply of commercially available automated blood group testing equipment for use as a secondary testing technology for ABO and Rh D typing, antibody screening and identification, extended red cell phenotyping and HbAS (heterozygous sickle cell trait) screening for donor blood, tissues and stem cell (haemopoietic progenitor cells and therapeutic cells) samples.
II.1.5) Estimated total value
Value excluding VAT:
8 655 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
38434520
85111810
38434520
48921000
71900000
71632000
II.2.3) Place of performance
NUTS code:
UK
II.2.4) Description of the procurement
NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, and IT provision of hardware, middleware and software, allowing interoperability over a private VPN between the supplier and NHSBT and connectivity to the NHSBT LIMS systems, and an overall on-going support mechanism that will be required to carry out the necessary testing as stated below.<br/><br/>A complete solution (test system) includes all necessary maintenance, consumables, software and overall support required to carry out the testing. All invitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. GB will continue to recognise CE marking until the UK requirements fully apply (subject to transitional arrangements set out for CE marked devices), in compliance with the UK Medical Devices Regulations 2002, as amended.<br/><br/>https://www.gov.uk/government/publications/implementation-of-the-future-regulation-of-medical-devices-and-extension-of-standstill-period/implementation-of-the-future-regulations<br/><br/>The system will be used in Filton (Bristol) and Manchester donor testing sites and the following is required for: (annual volume estimation in brackets):<br/><br/>- ABO (repeat tests from primary test systems and confirmatory testing (6,200 to 10,000).<br/>- RhD (repeat tests from primary test system and confirmatory testing) (8,000 to 10,000)<br/>- Antibody neat screen to detect clinically significant antibodies in plasma using a minimum of 3 screening cells (113,000)<br/>- Antibody titre testing (1:10 and 1:50) to detect clinically significant antibodies in plasma at those dilutions using a minimum of 3 screening cells (6,800)<br/>- Paediatric antibody neat screen to detect clinically significant antibodies in plasma using a minimum of 3 screening cells (135,000)<br/>- Fya (60,000 to 73,000)<br/>- Fyb (60,000 to 72,000)<br/>- k (10,000 to 12,000)<br/>- Lua (10,000)<br/>- Kpa (10,000)<br/>- Haemoglobin S screen suitable to test for HbAS (heterozygous sickle cell trait) for blood donation (70,000 to 84,000)<br/><br/>All test protocols must be in accordance with the Guidelines for the Blood Transfusion service in the United Kingdom (https://www.transfusionguidelines.org/red-book) and the Good Practice Guidelines for Blood Establishments that are required to comply with Directive 2005/62/EC. These are published in the 20th edition of the Guide to the preparation, use and quality assurance of blood components.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 655 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 60
This contract is subject to renewal: Yes
Description of renewals:
5 x 12 month extensions
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2023/S 000-030665
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
10/06/2024
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Tender must be valid until:
10/12/2024
IV.2.7) Conditions for opening of tenders
Date:
10/06/2024
Local time: 17:00
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
Yes
VI.4) Procedures for review
VI.4.1) Review body
The High Court
The Strand
London
WC2A 2LL
UK
Internet address(es)
URL: https://www.judiciary.uk/courts-and-tribunals/high-court/
VI.4.2) Body responsible for mediation procedures
The High Court
The Strand
London
WC2A 2LL
UK
Internet address(es)
URL: https://www.judiciary.uk/courts-and-tribunals/high-court/
VI.4.4) Service from which information about the review procedure may be obtained
The High Court
The Strand
London
WC2A 2LL
UK
Internet address(es)
URL: https://www.judiciary.uk/courts-and-tribunals/high-court/
VI.5) Date of dispatch of this notice
09/05/2024